proglumide has been researched along with Acute Disease in 24 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The therapeutic efficacy of a CCK-A receptor antagonist, loxiglumide, in patients with painful acute attacks of chronic pancreatitis was evaluated." | 9.10 | Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. ( Matsuno, S; Satake, K; Shiratori, K; Takeuchi, T, 2002) |
| "The therapeutic effects of loxiglumide on human acute pancreatitis was investigated in 104 Japanese institutes from October 1992 to March 1994." | 9.09 | Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. ( Harada, H; Ochi, K; Satake, K, 1999) |
| " In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop." | 7.70 | Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 7.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "The aim of this study was to investigate the effect of endogenous cholecystokinin (CCK) on pancreatic regeneration after acute hemorrhagic pancreatitis." | 7.69 | Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats. ( Kimura, T; Nakano, I; Nawata, H; Song, W; Yamaguchi, H, 1996) |
| "Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated." | 7.68 | Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 7.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats." | 7.68 | Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 7.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "Rats with acute experimental pancreatitis were treated with the cholecystokinin (CCK)-receptor antagonist proglumide." | 7.67 | Proglumide treatment in bile-induced acute experimental pancreatitis. ( Ihse, I; Larsson, L; Lilja, I; Tarpila, E, 1988) |
| "The effects of cholecystokinin receptor antagonist CR 1392 was studied in a model of mild acute pancreatitis induced in rats by four subcutaneous injections of the secretagogue caerulein." | 7.67 | Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats. ( Baba, S; Fujii, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayshi, Y; Otsuki, M; Tani, S, 1989) |
| "The aim of this study was to elucidate whether cholecystokinin (CCK) had a role in the occurrence and/or in the development of experimental acute pancreatitis in rats, and furthermore to find the possibility for the treatment of acute pancreatitis with a CCK antagonist, proglumide." | 7.67 | Possible role of cholecystokinin in the development of acute pancreatitis in rats. ( Fujimura, M; Shinya, H, 1989) |
| "Loxiglumide treatment, although significantly decreasing protein output, had no influence on pancreatic weight, protein and DNA contents, or pancreatic juice flow but increased the amylase and lipase contents compared to those of the saline-treated postpancreatitic rats." | 5.29 | Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. ( Nakano, S; Otsuki, M; Tachibana, I, 1995) |
| "The therapeutic efficacy of a CCK-A receptor antagonist, loxiglumide, in patients with painful acute attacks of chronic pancreatitis was evaluated." | 5.10 | Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. ( Matsuno, S; Satake, K; Shiratori, K; Takeuchi, T, 2002) |
| "The therapeutic effects of loxiglumide on human acute pancreatitis was investigated in 104 Japanese institutes from October 1992 to March 1994." | 5.09 | Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. ( Harada, H; Ochi, K; Satake, K, 1999) |
| " In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop." | 3.70 | Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 3.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "The aim of this study was to investigate the effect of endogenous cholecystokinin (CCK) on pancreatic regeneration after acute hemorrhagic pancreatitis." | 3.69 | Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats. ( Kimura, T; Nakano, I; Nawata, H; Song, W; Yamaguchi, H, 1996) |
| "Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively." | 3.69 | Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997) |
| "Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated." | 3.68 | Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 3.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats." | 3.68 | Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 3.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "Rats with acute experimental pancreatitis were treated with the cholecystokinin (CCK)-receptor antagonist proglumide." | 3.67 | Proglumide treatment in bile-induced acute experimental pancreatitis. ( Ihse, I; Larsson, L; Lilja, I; Tarpila, E, 1988) |
| "The effects of cholecystokinin receptor antagonist CR 1392 was studied in a model of mild acute pancreatitis induced in rats by four subcutaneous injections of the secretagogue caerulein." | 3.67 | Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats. ( Baba, S; Fujii, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayshi, Y; Otsuki, M; Tani, S, 1989) |
| "The aim of this study was to elucidate whether cholecystokinin (CCK) had a role in the occurrence and/or in the development of experimental acute pancreatitis in rats, and furthermore to find the possibility for the treatment of acute pancreatitis with a CCK antagonist, proglumide." | 3.67 | Possible role of cholecystokinin in the development of acute pancreatitis in rats. ( Fujimura, M; Shinya, H, 1989) |
| "Morphine was administered by subcutaneous (s." | 1.30 | Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice. ( Pol, O; Puig, MM, 1997) |
| "Treatment with loxiglumide (Loxi-3 and Loxi-4) or CCK-8 for 6 days (CCK-4) or with a high dose of loxiglumide for the first 3 days (Loxi-2) significantly suppressed the recovery of pancreatic weight and DNA content compared to saline treatment or to the untreated normal control rats." | 1.30 | CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats. ( Kihara, Y; Nakano, S; Otsuki, M, 1998) |
| "Loxiglumide treatment, although significantly decreasing protein output, had no influence on pancreatic weight, protein and DNA contents, or pancreatic juice flow but increased the amylase and lipase contents compared to those of the saline-treated postpancreatitic rats." | 1.29 | Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. ( Nakano, S; Otsuki, M; Tachibana, I, 1995) |
| "Treatment with loxiglumide (50 mg/kg body weight), CCK-8 (2." | 1.29 | Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats. ( Nakano, S; Otsuki, M; Tachibana, I, 1994) |
| "The histological signs of acute pancreatitis were greatly alleviated by fasting." | 1.28 | Fasting prevents acute pancreatitis induced by cerulein in rats. ( Fujii, M; Fujisawa, T; Itoh, H; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (25.00) | 18.7374 |
| 1990's | 15 (62.50) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiratori, K | 1 |
| Takeuchi, T | 1 |
| Satake, K | 2 |
| Matsuno, S | 1 |
| Latorre, M | 1 |
| Bartolomé-Nebreda, JM | 1 |
| García-López, MT | 1 |
| González-Muñiz, R | 1 |
| Herranz, R | 1 |
| Del Río, J | 1 |
| Cenarruzabeitia, E | 1 |
| Takase, K | 1 |
| Ueda, T | 1 |
| Kuroda, Y | 1 |
| Nakano, S | 3 |
| Tachibana, I | 2 |
| Otsuki, M | 9 |
| Nakae, Y | 1 |
| Naruse, S | 1 |
| Kitagawa, M | 1 |
| Hirao, S | 1 |
| Yamamoto, R | 1 |
| Hayakawa, T | 1 |
| Tani, S | 6 |
| Itoh, H | 5 |
| Koide, M | 2 |
| Okabayashi, Y | 4 |
| Song, W | 1 |
| Yamaguchi, H | 1 |
| Nakano, I | 1 |
| Kimura, T | 1 |
| Nawata, H | 1 |
| Czakó, L | 1 |
| Yamamoto, M | 1 |
| Taniguchi, H | 1 |
| Yomota, E | 1 |
| Kume, E | 1 |
| Shikano, T | 1 |
| Endo, T | 1 |
| Nagasaki, M | 1 |
| Pol, O | 1 |
| Puig, MM | 1 |
| Kihara, Y | 1 |
| Kimura, K | 1 |
| Tominaga, K | 1 |
| Fujii, M | 4 |
| Saito, T | 1 |
| Kasai, H | 1 |
| Ochi, K | 1 |
| Harada, H | 1 |
| Fuji, M | 1 |
| Nakamura, T | 4 |
| Fujisawa, T | 3 |
| Grönroos, JM | 1 |
| Aho, HJ | 1 |
| Hietaranta, AJ | 1 |
| Nevalainen, TJ | 1 |
| Niederau, C | 2 |
| Liddle, RA | 1 |
| Ferrell, LD | 2 |
| Grendell, JH | 2 |
| Tarpila, E | 1 |
| Larsson, L | 1 |
| Lilja, I | 1 |
| Ihse, I | 1 |
| Okabayshi, Y | 1 |
| Baba, S | 1 |
| Shinya, H | 1 |
| Fujimura, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study[NCT03686618] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for proglumide and Acute Disease
| Article | Year |
|---|---|
[New aspects of pharmaco-therapy for acute pancreatitis].
Topics: Acute Disease; Animals; Blood Proteins; Clinical Trials as Topic; Drug Design; Humans; Imidazoles; L | 2004 |
2 trials available for proglumide and Acute Disease
| Article | Year |
|---|---|
Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Topics: Acute Disease; Administration, Oral; Adult; Amylases; Chronic Disease; Female; Hormone Antagonists; | 2002 |
Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan.
Topics: Abdominal Pain; Acute Disease; Adult; Amylases; Dose-Response Relationship, Drug; Female; Hormone An | 1999 |
21 other studies available for proglumide and Acute Disease
| Article | Year |
|---|---|
Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
Topics: Acute Disease; alpha-Amylases; Animals; Binding, Competitive; Cerebral Cortex; Cholecystokinin; Deva | 2004 |
Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; DNA; Lipase; Male; Pancreas; Pancreatitis; Proglumide; Proteins; R | 1995 |
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan | 1995 |
Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Disease Models, Animal; Duodenum; Lipase; Male; P | 1993 |
Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
Topics: Acute Disease; Animals; Ceruletide; Glucose; Injections, Intravenous; Injections, Subcutaneous; Insu | 1994 |
Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats.
Topics: Acute Disease; Animals; Cholecystokinin; Hemorrhage; Male; Pancreas; Pancreatitis; Proglumide; Rats; | 1996 |
Pancreatic fluid hypersecretion in rats after acute pancreatitis.
Topics: Acute Disease; Animals; Antibodies; Atropine; Bicarbonates; Cell Division; Ceruletide; Chlorides; Ch | 1997 |
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate | 1997 |
Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice.
Topics: Acute Disease; Animals; Cholecystokinin; Dizocilpine Maleate; Drug Tolerance; Enteritis; Gastrointes | 1997 |
CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Cholecystokinin; DNA; Hormone Antagonists; Lipase; Mal | 1998 |
Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Duodenum; Female; Gabexate; Hormone Antagonists; Injec | 1998 |
Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Esters; Gabexate; Guanidines; Male; Organ Size; Pancre | 1990 |
Early acinar cell changes in caerulein-induced interstitial acute pancreatitis in the rat.
Topics: Acute Disease; Animals; Ceruletide; Cycloleucine; Cytoplasm; Cytoplasmic Granules; Enzyme Precursors | 1991 |
Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Disease Models, Animal; Glutamine; Male; Pancre | 1990 |
Fasting prevents acute pancreatitis induced by cerulein in rats.
Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Fasting; Male; Pancreas; Pancreatitis; Proglumi | 1990 |
Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Choline Deficiency; Disease Models, Animal; Ethio | 1986 |
Proglumide treatment in bile-induced acute experimental pancreatitis.
Topics: Acute Disease; Amylases; Animals; Bile; Glutamine; Male; Pancreatitis; Proglumide; Rats; Rats, Inbre | 1988 |
Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Glutamine; Humans; Male; Organ Size; Pancreas; Pancrea | 1989 |
Possible role of cholecystokinin in the development of acute pancreatitis in rats.
Topics: Acute Disease; Animals; Cholecystokinin; Male; Pancreatitis; Proglumide; Rats; Rats, Inbred Strains | 1989 |
Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin.
Topics: Acute Disease; Animals; Benzamides; Ceruletide; Dose-Response Relationship, Drug; Glutamine; Male; M | 1985 |
Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392.
Topics: Acute Disease; Animals; Ceruletide; Disease Models, Animal; Dose-Response Relationship, Drug; Glutam | 1988 |